Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 183

1.

MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity.

Huijbers MG, Vergoossen DL, Fillié-Grijpma YE, van Es IE, Koning MT, Slot LM, Veelken H, Plomp JJ, van der Maarel SM, Verschuuren JJ.

Neurol Neuroimmunol Neuroinflamm. 2019 Feb 21;6(3):e547. doi: 10.1212/NXI.0000000000000547. eCollection 2019 May.

2.

Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study.

Ricotti V, Selby V, Ridout D, Domingos J, Decostre V, Mayhew A, Eagle M, Butler J, Guglieri M, Van der Holst M, Jansen M, Verschuuren JJGM, de Groot IJM, Niks EH, Servais L, Straub V, Voit T, Hogrel JY, Muntoni F.

Neuromuscul Disord. 2019 Feb 19. pii: S0960-8966(18)31379-8. doi: 10.1016/j.nmd.2019.02.002. [Epub ahead of print]

PMID:
30852071
3.

Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.

Huijbers MG, Plomp JJ, van Es IE, Fillié-Grijpma YE, Kamar-Al Majidi S, Ulrichts P, de Haard H, Hofman E, van der Maarel SM, Verschuuren JJ.

Exp Neurol. 2019 Mar 6;317:133-143. doi: 10.1016/j.expneurol.2019.03.001. [Epub ahead of print]

4.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25.

PMID:
30692052
5.

A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis.

Strijbos E, Tannemaat MR, Alleman I, de Meel RHP, Bakker JA, van Beek R, Kroon FP, Rimmelzwaan GF, Verschuuren JJGM.

Vaccine. 2019 Feb 8;37(7):919-925. doi: 10.1016/j.vaccine.2019.01.007. Epub 2019 Jan 16.

PMID:
30660402
6.

The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders.

Maddison P, Titulaer MJ, Verschuuren JJ, Gozzard P, Lang B, Irani SR, Sabater L, Graus F, Murray A, Chapman CJ.

J Neuroimmunol. 2019 Jan 15;326:14-18. doi: 10.1016/j.jneuroim.2018.11.003. Epub 2018 Nov 8.

7.

Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.

de Meel RHP, Raadsheer WF, van Zwet EW, Verschuuren JJGM, Tannemaat MR.

Eur J Neurol. 2018 Nov 12. doi: 10.1111/ene.13867. [Epub ahead of print]

PMID:
30417962
8.

Serum Acetylcholine Receptor Antibodies Before the Clinical Onset of Myasthenia Gravis.

Strijbos E, Verschuuren JJGM, Kuks JBM.

J Neuromuscul Dis. 2018;5(2):261-264. doi: 10.3233/JND-180313.

PMID:
29865092
9.

Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice.

van der Pijl EM, van Putten M, Niks EH, Verschuuren JJGM, Aartsma-Rus A, Plomp JJ.

Neuromuscul Disord. 2018 May;28(5):427-442. doi: 10.1016/j.nmd.2018.02.013. Epub 2018 Mar 6.

10.

Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients.

Catapano F, Domingos J, Perry M, Ricotti V, Phillips L, Servais L, Seferian A, Groot I, Krom YD, Niks EH, Verschuuren JJ, Straub V, Voit T, Morgan J, Muntoni F.

Epigenomics. 2018 Jul;10(7):875-889. doi: 10.2217/epi-2018-0022. Epub 2018 Mar 22.

PMID:
29564913
11.

Author Correction: Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy.

Doorenweerd N, Mahfouz A, van Putten M, Kaliyaperumal R, T' Hoen PAC, Hendriksen JGM, Aartsma-Rus AM, Verschuuren JJGM, Niks EH, Reinders MJT, Kan HE, Lelieveldt BPF.

Sci Rep. 2018 Mar 1;8(1):4058. doi: 10.1038/s41598-018-22154-7.

12.

Distinct representation of muscle weakness in QMG and MG-ADL.

de Meel RHP, Verschuuren JJGM, Tannemaat MR.

Lancet Neurol. 2018 Mar;17(3):204-205. doi: 10.1016/S1474-4422(18)30037-1. No abstract available.

PMID:
29452679
13.

IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.

Huijbers MG, Plomp JJ, van der Maarel SM, Verschuuren JJ.

Ann N Y Acad Sci. 2018 Feb;1413(1):92-103. doi: 10.1111/nyas.13561. Epub 2018 Jan 28. Review.

14.

Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies.

Verschuuren JJGM, Plomp JJ, Burden SJ, Zhang W, Fillié-Grijpma YE, Stienstra-van Es IE, Niks EH, Losen M, van der Maarel SM, Huijbers MG.

Ann N Y Acad Sci. 2018 Feb;1413(1):111-118. doi: 10.1111/nyas.13543. Epub 2018 Jan 21. Review.

PMID:
29356029
15.

Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne.

Lourbakos A, Yau N, de Bruijn P, Hiller M, Kozaczynska K, Jean-Baptiste R, Reza M, Wolterbeek R, Koeks Z, Ayoglu B, de Klerk D, Campion G, Zaharieva I, Nadarajah VD, Nilsson P, Al-Khalili Szigyarto C, Muntoni F, Lochmüller H, Verschuuren JJ, Goemans N, Tulinius M, Niks EH, de Kimpe S, Aartsma-Rus A, 't Hoen PAC, Spitali P.

Sci Rep. 2017 Dec 20;7(1):17888. doi: 10.1038/s41598-017-17982-y.

16.

Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis.

Badrising UA, Tsonaka R, Hiller M, Niks EH, Evangelista T, Lochmüller H, Verschuuren JJ, Aartsma-Rus A, Spitali P.

J Neuromuscul Dis. 2017;4(4):327-335. doi: 10.3233/JND-170234.

PMID:
29172005
17.

Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database.

Koeks Z, Bladen CL, Salgado D, van Zwet E, Pogoryelova O, McMacken G, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Bellgard MI, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Dai Y, Wang J, Barišić N, Brabec P, Lähdetie J, Walter MC, Schreiber-Katz O, Karcagi V, Garami M, Herczegfalvi A, Viswanathan V, Bayat F, Buccella F, Ferlini A, Kimura E, van den Bergen JC, Rodrigues M, Roxburgh R, Lusakowska A, Kostera-Pruszczyk A, Santos R, Neagu E, Artemieva S, Rasic VM, Vojinovic D, Posada M, Bloetzer C, Klein A, Díaz-Manera J, Gallardo E, Karaduman AA, Oznur T, Topaloğlu H, El Sherif R, Stringer A, Shatillo AV, Martin AS, Peay HL, Kirschner J, Flanigan KM, Straub V, Bushby K, Béroud C, Verschuuren JJ, Lochmüller H.

J Neuromuscul Dis. 2017;4(4):293-306. doi: 10.3233/JND-170280.

18.

Neuromuscular synapse electrophysiology in myasthenia gravis animal models.

Plomp JJ, Huijbers MGM, Verschuuren JJGM.

Ann N Y Acad Sci. 2018 Jan;1412(1):146-153. doi: 10.1111/nyas.13507. Epub 2017 Oct 25. Review.

PMID:
29068559
19.

A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis.

Strijbos E, Huijbers MG, van Es IE, Alleman I, van Ostaijen-Ten Dam MM, Bakker J, van Zwet EW, Jol-van der Zijde CM, van Tol MD, Verschuuren JJ.

Vaccine. 2017 Nov 1;35(46):6290-6296. doi: 10.1016/j.vaccine.2017.09.078. Epub 2017 Oct 6.

PMID:
28992975
20.

Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy.

Doorenweerd N, Mahfouz A, van Putten M, Kaliyaperumal R, T' Hoen PAC, Hendriksen JGM, Aartsma-Rus AM, Verschuuren JJGM, Niks EH, Reinders MJT, Kan HE, Lelieveldt BPF.

Sci Rep. 2017 Oct 3;7(1):12575. doi: 10.1038/s41598-017-12981-5. Erratum in: Sci Rep. 2018 Mar 1;8(1):4058.

Supplemental Content

Loading ...
Support Center